The « Premium Drug Profiling » offers a fast answer for the Biotechnology companies and the Pharmaceutical Groups regarding the therapeutic response of their future drugs in Humans.
ProfileHIT represents a unique opportunity for its customers to directly assess in vitro, the response of a drug candidate on the Human vascular peripheral system, before its first administration in Human.
As our screening-strategy can be done before the pre-clinical phases, it enables to exclude out of the pipeline some of the compounds which could present toxicities over the further testing-procedures. Thus, this approach enables the prevention of unnecessary investments for the companies.